Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study

Neurology

Volumn 77, Issue 4, 2011, Pages 355-363

  Noyes, K ^a   Bajorska, A ^a   Chappel, A ^a,e   Schwid, S R ^a   Mehta, L R ^b   Weinstock Guttman, B ^c   Holloway, R G ^a   Dick, A W ^d  

^a UNIVERSITY OF ROCHESTER   (United States)

^b Evergreen Neuroscience Institute   (United States)

^c JACOBS NEUROLOGICAL INSTITUTE   (United States)

^d RAND CORPORATION   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UNEMPLOYMENT; UNITED STATES;

EID: 79959385154     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182270402     Document Type: Article

References (35)

1. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294. (Pubitemid 26100751)
3. PRISMS. PRISMS-4: long-term efficacy of interferonbeta- 1a in relapsing MS. Neurology 2001;56:1628-1636.
4. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-708.
5. Polman C, O'Connor RW, Havrdova E, et al. A randomized placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
6. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025. (Pubitemid 36026580)
7. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Costeffectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-568. (Pubitemid 39390836)
8. Bell C, Graham J, Earnshaw S, Oleen-Burkley MK, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-261. (Pubitemid 46730893)
9. Tappenden P, McCabe C, Chilcott JB, et al. Costeffectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population. Value Health Epub 2009.
10. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther 2003;25:611-634. (Pubitemid 36286924)
11. Brown MG. Effectiveness and Cost-Effectiveness of New Multiple Sclerosis Drugs in the 'Real World': project number: 6795-15-2001/4410011, 1-32. Halifax, Nova Scotia, Capital Health Nova Scotia, and Dalhousie University; 2004.
12. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis: commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522-526.
13. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-149. (Pubitemid 30245835)
14. Kobelt G, Jonsson L, Miltenburger C, Jonsson B. Costutility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health Care 2002;18:127-138. (Pubitemid 34408535)
15. Rubio-Terres C, Dominguez-Gil HA. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain.] Rev Neurol 2005;40:705-710. (Pubitemid 47279272)
16. Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics 2000;18:45-53. (Pubitemid 30468867)
17. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002;5:44-54. (Pubitemid 34160370)
18. Kobelt G, Jonsson L, Fredrikson S. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ 2003;4:50-59. (Pubitemid 36457057)
19. Minden SL, Frankel D, Hadden LS, Perloff JN, Srinath KP, Hoaglin DC. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006;12:24-38. (Pubitemid 43169235)
20. Minden SL, Frankel D, Hadden LS, Srinath KP, Perloff JN. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. Neurorehabilitation 2004; 19:55-67. (Pubitemid 38241492)
21. Minden S, Hoaglin D, Jureidini S, Hadden L, Komatsuzaki Y, Outley J. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. 2008;14:640-655.
22. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
23. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999;5:349-354. (Pubitemid 29505050)
24. STATA data analysis. College Station, TX: StataCorp LP; 2010.
25. Current Employment Statistics. Washington, DC: The Bureau of Labor Statistics; 2010.
26. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care 2000; 38:1022-1028.
27. Ware JE Jr, Sherbourne CD. The MOS 36-item shortform health survey (SF-36): I: conceptual framework and item selection. Med Care 1992;30:473-483.
28. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes 2003;1:4.
29. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004;13:405-415. (Pubitemid 38660390)
30. Tufts Cost-Effectiveness Registry: 2010. Available at: https://research.tufts-nemc.org/cear/default.aspx. Accessed June 13, 2011.
31. Pickin M, Cooper CL, Chater T, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study: early results and lessons for the future. BMC Neurol 2009;9:1-8.
32. Rafley J. Costly failure of a risk sharing scheme. BMJ Epub 2010 12 Jun.
33. Kobelt G. Cost-utility analysis of interferon B-1B in the treatment of different types of multiple sclerosis: 1: 7-28- 2001: SSE/EFI Working Paper Series in Economics and Finance No. 459. High Wycombe, Bucks, UK: Health Dynamics International; 2001.
34. Kobelt G, Berg J, Atherley D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Neurology 2006;66:1696-1702. (Pubitemid 43964625)
35. Tappenden P, Chilcott J, O'Hagan T, et al. Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis: 1. Sheffield, UK: Centre for Bayesian Statistics in Health Economics, University of Sheffield; 2001.